This phase II trial demonstrated that the combination of camrelizumab and apatinib in refractory chordoma achieved an objective response rate of 24.2% by RECIST and 48.5% by Choi criteria, with a median progression-free survival of 28.4 months by RECIST. The safety profile was manageable, with liver enzyme elevations as the most common severe adverse events. CDKN2A alterations were identified as a negative prognostic biomarker.
Study
|
Investigator-initiated, single-center, phase II trial [ChiCTR2100042938] |
| Patients with refractory chordoma (n=33) |
| Camrelizumab 200 mg every 2 weeks plus apatinib 250 mg and 500 mg on alternate days, 4-week cycles
|
Efficacy
|
ORR: 24.2% (8/33 pts) |
| mDoR: not reached |
| DCR: 90.9% |
| mPFS: 28.4 mos |
| 12-mo PFS: 70.0%
|
Safety
|
Dose interruption of apatinib (39.4%), dose reduction of apatinib (18.2%), dose interruption of camrelizumab (21.2%) |
| Drug discontinuation due to adverse events (12.1%) |
| No treatment-related deaths
|
J Clin Oncol. Published online May 13, 2026
http://doi.org/10.1200/JCO-25-02719
Reviewed by Ulas D. Bayraktar, MD on Jun 12, 2026
